The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASCO 2024 | The safety and efficacy of Grb2 inhibition with BP1001 in AML
Jorge Cortes, MD, Georgia Cancer Center, Augusta University, Augusta, GA, discusses BP1001, an oligonucleotide targeting Grb2 currently under investigation for treating acute myeloid leukemia (AML). In combination with low-dose cytarabine, BP1001 has shown strong efficacy and excellent tolerability, with no toxicity signals. Dr Cortes also highlights its potential for combination with other targeted therapies. This interview took place during the 2024 American Society of Clinical Oncology (ASCO) Meeting in Chicago, IL.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
